EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis

Jorge Plutzky iD, Paweł Bogdański iD, Helen M Colhoun, Selçuk Dağdelen iD, John E Deanfield, Scott S Emerson, G Kees Hovingh iD, Steven E Kahn iD, Kathrine Ekström, Gustavs Latkovskis iD, Michael Lehrke iD, Søren Hardt-Lindberg und 8 weitere

Circulation · 2026

DOI: 10.1161/circulationaha.125.074482 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Circulation, 2026. Verfasst von Jorge Plutzky und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine (J.P.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: C-Reactive Protein, Cardiovascular Diseases, Obesity, Overweight. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity), among 17 604 patients with known atherosclerotic cardiovascular disease and overweight or obesity, but not diabetes, randomization to the glucagon-like peptide-1 receptor agonist semaglutide significantly reduced the primary outcome of major adverse cardiovascular events (MACE; cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) compared with placebo (mean follow-up, 39.8 months). Inflammation, as indicated by plasma hsCRP (high-sensitivity C-reactive protein) level, is implicated as a biomarker predicting cardiovascular risk in obesity and atherosclerotic cardiovascular disease. SELECT provides a unique opportunity to study the relationship among hsCRP, obesity, weight loss, and MACE outcomes in semaglutide versus placebo groups. METHODS: In this prespecified SELECT substudy, we evaluated whether baseline hsCRP levels predicted MACE risk and examined the relationships between changes in hsCRP levels and time to first MACE, baseline body weight, weight loss, and other clinical measures among treatment groups over time (104, 208 weeks) using multiple approaches, including Cox modeling. RESULTS: Baseline hsCRP level, which was similar in the semaglutide (geometric mean 1.96 mg/L) and placebo (geometric mean 1.91 mg/L) groups, was prognostic of future MACE. The risk of MACE increased across baseline hsCRP level

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

C-Reactive ProteinCardiovascular DiseasesObesityOverweightSemaglutideAgedFemaleHumansMaleMiddle AgedBiomarkersDouble-Blind MethodInflammationWeight LossAnti-Obesity AgentsGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

atherosclerosiscardiovascular diseasesglucagon-like peptide-1 receptor agonistsinflammationobesitysemaglutide

Substanzen

BiomarkersC-Reactive ProteinSemaglutideAnti-Obesity AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine (J.P.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Department of Treatment of Obesity, Metabolic Disorders, and Clinical Dietetics, Poznan University of Medical Sciences, Poland (P.B.).
  • Institute of Genetics and Cancer, University of Edinburgh, Scotland (H.M.C.).
  • Department of Endocrinology and Metabolism, School of Medicine, Hacettepe University, Ankara, Turkey (S.D.).
  • Institute of Cardiovascular Science, University College London, UK (J.E.D.).
  • Department of Biostatistics, University of Washington, Seattle (S.S.E.).

ORCID-Profile: Jorge Plutzky, Paweł Bogdański, Selçuk Dağdelen, G Kees Hovingh, Steven E Kahn, Gustavs Latkovskis, Michael Lehrke, Ildiko Lingvay, Stephen J Nicholls, Tugce Kalayci Oral, Paul M Ridker, Donna H Ryan, A Michael Lincoff

Zitieren

APA

Plutzky, J., Bogdański, P., Colhoun, H. M., Dağdelen, S., Deanfield, J. E., Emerson, S. S., Hovingh, G. K., Kahn, S. E., Ekström, K., Latkovskis, G., Lehrke, M., Hardt-Lindberg, S., Lingvay, I., Nicholls, S. J., Kalayci Oral, T., Terns, P. P., Rasmussen, S., Ridker, P. M., Ryan, D. H., & Lincoff, A. M. (2026). Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis. Circulation. https://doi.org/10.1161/circulationaha.125.074482

Vancouver

Plutzky J, Bogdański P, Colhoun HM, Dağdelen S, Deanfield JE, Emerson SS, et al. Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis. Circulation. 2026. doi:10.1161/circulationaha.125.074482

BibTeX
@article{Plutzky2026,
  author = {Plutzky, Jorge and Bogdański, Paweł and Colhoun, Helen M and Dağdelen, Selçuk and Deanfield, John E and Emerson, Scott S and Hovingh, G Kees and Kahn, Steven E and Ekström, Kathrine and Latkovskis, Gustavs and Lehrke, Michael and Hardt-Lindberg, Søren and Lingvay, Ildiko and Nicholls, Stephen J and Kalayci Oral, Tugce and Terns, Paula P and Rasmussen, Søren and Ridker, Paul M and Ryan, Donna H and Lincoff, A Michael},
  title = {Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis},
  journal = {Circulation},
  year = {2026},
  doi = {10.1161/circulationaha.125.074482}
}
Kostenlos starten →